mobocertinib takeda TAK structure EGFR exon 20 inhibitor ex20 Drug Hunter molecules of the year

EGFR exon 20 mutant inhibitor, oral once-daily

Breakthrough Therapy for ex20+ NSCLC (Ph. I)

from cellular screening + SBDD

mobocertinib

ARIAD/Takeda, Cambridge, MA

The ARIAD/Takeda EGFR exon 20 insertion mutant (EGFRex20ins) inhibitor TAK-788 is a Breakthrough Therapy for patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 20 insertion mutations.  The appearance…


     this content is exclusive to
    Premium members

    Unlock this content with a Premium membership to read it now.